Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug

Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease Prader-Willi syndrome. This blockbuster prospect complements Crenessity, a Neurocrine drug approved for treating a rare endocrine disorder called congenital adrenal hyperplasia. The post Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug appeared first on MedCity…

Read More

What Will Separate Healthcare AI Winners From Losers?

Uma Veerappan of Flare Capital Partners thinks the healthcare AI startups that will come out on top will be companies that integrate seamlessly into workflows, build proprietary datasets and quickly determine how to sell their technology. The post What Will Separate Healthcare AI Winners From Losers? appeared first on MedCity News.

Read More

Join the Fight Against Chronic Pain: It’s Time for Breakthrough Legislation in Congress

Over the past 15 years, financial and administrative barriers – most notably step therapy mandates and prior authorization requirements – have repeatedly forced patients through suboptimal or ineffective treatments before they can try another therapy, have tied the hands of healthcare professionals and patients alike. Now there’s a possible solution. The post Join the Fight…

Read More